COVID-19 Update (3/23/2020)

**UPDATE**

The coronavirus disease 2019 (COVID-19) outbreak is a rapidly evolving event, and CMS is monitoring the situation closely. We would like to reassure our valued patients and system partners that we are working hard to ensure minimal disruptions to our current or future operations.

We also understand that our patients are some of the most vulnerable segments of the population for the risk-factors associated with COVID-19. As such, we have been working hard to ensure we are prepared to respond to the needs of our patients and the communities where our clinics reside.

We are talking with all of our system partners to ensure medications and supplies remain available. We are also working diligently with all state and federal agencies to ensure regulatory barriers to not hinder sustainment and access to the highest quality care. We have developed a three-tier approach to handling the COVID-19 outbreak, in accordance with our guiding principles, as outlined below.

**GUIDING PRINCIPLES**

Our core tenants guiding our response to this pandemic are as follows:

- The opioid epidemic will be claiming lives long after the COVID-19 pandemic has subsided. It is imperative that we continue conducting intakes and minimize disruption to our patients’ care, while taking the necessary steps to accommodate the needs of all our stakeholders.
- Our patients have a higher risk to COVID-19 than the general population due to the higher rates of co-morbid conditions.
- We are working with state and federal agencies, but the situation is changing rapidly. We will respond as quickly as possible to implement all policy and regulatory changes as they are communicated to us.
- As a national leader in the addiction treatment space, we will make ourselves readily available to all key stakeholders to share our best practices and learned experiences.
- Cross functional teams and collaboration are imperative to ensure our employees and system partners are communicating, preventing redundant efforts, and aligning our focus towards the common goal of providing the highest quality care to our patients and the communities in which our clinics reside.
- Technology and innovation must be leveraged to the greatest extent possible to ensure the scalability of our operations.

**RESPONSE LEVELS**

Our operational response to the COVID-19 Outbreak is broken into the following three levels:

**LEVEL ONE**
Preventative measures at all sites; if there have been no identified exposures to COVID-19 directly related to the clinic staff or patients.

1.0 3/13/2020
1.1 3/16/2020

**LEVEL TWO**
Preventative measures plus adjusted staff schedules

2.0 3/17/2020
2.1 3/23/2020

**LEVEL THREE**
Preventative measures plus adjusted staff schedules and significant reduction of onsite staff; attempts to increase take-home levels if allowed by SAMHSA
SUMMARY OF LEVEL 1

- Increased frequency in cleaning our facilities
- Increased staff training and education
- Minimized client contact
- Contingency plans for continuation of all services (medication, counseling, case management) for patients at high risk of complications

SUMMARY OF LEVEL 2

- Protocol from Level 1 continues
- Adjusted staff schedules and implementation of a work-at-home program for applicable employees
- Critical functions identified by location and modifications to existing schedules to accommodate clinic needs
- Level Two exceptions for take-home medication as permitted by states (ultimate discretion remains the responsibility of medical providers)
  - While the Substance Abuse and Mental Health Services Administration (SAMHSA) has released federal guidance allowing more lenient take-home options, each state has the authority to set standards at their own discretion. As such, it’s important to note that the guidance is state-by-state specific. As information is released on state-level implementation of the SAMHSA recommendations, we will update our policies and procedures to reflect the most up-to-date information.
- TB, RPR, or other required bloodwork to be done contingent on PPE availability for nursing staff
- Naloxone policy remains in place – all intakes and high-risk patients must be offered a kit (if available) or a prescription
- Daily meetings with local and regional leadership, medical providers, quality management, and other key functions

SUMMARY OF LEVEL 2.1

- Protocol from Level 2 continues
- Additional PPE guidelines and instructions
- Activation of Engage, the companion application to our EHR to allow patients to check in remotely and view other clinic information important to their treatment
- Patient and employee verification letters for locations in states with stay at home or lockdown protocols in place

NEW PATIENTS

Community Medical Services will continue to provide intakes for new patients. MAT is a life-saving treatment and CMS will continue to offer this to patients during this crisis, while taking appropriate precautions to protect other patients and staff. We understand that the opioid crisis does not lessen as a result of the COVID-19 outbreak. CMS is doing everything within our control to ensure that those suffering from OUD who are ready to enter treatment still have the opportunity to do so.

FURTHER GUIDANCE

Community Medical Services is dedicated to remaining open and ensuring all patients continue with their medication as scheduled while limiting exposure for patients and staff. If you are at risk for complications, have been placed on quarantine by your medical provider, or were confirmed to have COVID-19, please call your clinic to make arrangements for your continued treatment.
As we monitor the COVID-19 outbreak, we will continue to communicate with our patients and stakeholders to notify them of changes in protocols and clinic hours of operation. Please speak with clinic staff regarding any questions or concerns you may have.

**RESOURCES**
For latest information on federal and state guidance towards treatment providers that are informing the preceding changes, please see below.

**MEDICATED-ASSISTED TREATMENT (MAT)**
- DEA Guidance: [Exemption Allowing Alternate Delivery Methods for OTPs](#)
- DEA Guidance: [Use of Teledicine While Providing Medication Assisted Treatment (MAT)](#)
- Substance Abuse and Mental Health Services Administration (SAMHSA): [OTP Update Page](#)
- SAMHSA: [COVID-19 Guidance for Opioid Treatment Programs](#)

**IMPORTANT FEDERAL LINKS**
- Government Response to Coronavirus, COVID-19
- Centers for Disease Control and Prevention
- Department of Health and Human Services
- Substance Abuse and Mental Health Services Administration
- DEA Significant Guidance Document Portal
- Federal Emergency Management Agency
- [Coronavirus.gov](#)

The health and safety of our patients and staff has, and always will be, our top priority.